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Background: Aspergillus infection was mostly reported with high mortality rates and a bad prognosis in
immunocompromised patients, but data were lacking on the clinical characteristics of aspergillus infection in liver
cirrhosis. The aim of this study was to retrospectively assess the morbidity and mortality rate, clinical manifestation,
risk factors, and medication of invasive pulmonary aspergillosis (IPA) in liver cirrhosis in The First Affiliated Hospital,
College of Medicine, Zhejiang University.
Methods: Patients with liver cirrhosis who had been diagnosed with proven or probable IPA by clinical and
laboratory parameters from 1st December 2008 to 1st May2012 were retrospectively evaluated for predisposing
factors for IPA and clinical outcome. The follow up ended on 30th July2012. IPA was defined according to European
Organization for Research and Treatment of Cancer/Mysoses Study group criteria.
Results: In total, 6,600 patients with liver cirrhosis were enrolled, and 19 out of these developed IPA. Seventeen out
of 19 patients died. Imaging findings such as the halo sign and lower respiratory tract infection symptoms
contributed to the early diagnosis of IPA. Possible risk factors for IPA included a high Child-Turcotte-Pugh (CTP)
score, broad antibiotic usage and steroid exposure. The use of antifungal compounds may prolong a patient’s life.
Conclusions: The mortality of liver cirrhosis with IPA is high. Liver cirrhosis should be considered a risk factor of
IPA. Once patients with high CTP scores and steroid and broad spectrum antibiotics exposure present cough and
fever, IPA should be taken into consideration and antifungal agents should be used as soon as possible.
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Aspergillus species have emerged as an important cause of
life-threatening infections in immunocompromised patients
with prolonged neutropenia and immunodeficiency who
have undergone hematopoietic stem cell transplantation
and liver transplantation [1-3]. Moreover, an expanding
spectrum of patients at risk for invasive Aspergillus has re-
cently been indicated. High risk (allogeneic bone marrow
transplant, neutropenia and hematological cancer), inter-
mediate risk (autologous bone marrow transplant, malnu-
trition, corticosteroids, HIV, solid organ transplant,
diabetes, underlying pulmonary diseases and solid organ* Correspondence: ljli@zju.edu.cn
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stated.cancer) and low risk (cystic fibrosis and connective tissue
disease) have been described in the literature [4]. Data have
shown that invasive aspergillosis is a devastating infectious
disease in patients within the intensive care unit even with-
out the presence of an apparent predisposing immunodefi-
ciency [5-7]. Liver cirrhosis has many complications, such
as upper gastric bleeding and hepatoencephalopathy, due
to portal vein hypertension. All of these complications were
fatal. Infection was also a common cause of death. Some
studies have focused on invasive pulmonary aspergillosis
(IPA) after liver transplantation [3,7]. However, it was rarely
reported in patients with liver cirrhosis during pre-
transplant period [8].
As such, we retrospectively investigated patients with
liver cirrhosis and invasive pulmonary aspergillosis and ana-
lyzed their morbility and mortality rate, clinical characteris-
tics and possible risk factors in The First Affiliated Hospital,
College of Medicine, Zhejiang University.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori ap-
proval by The Human Ethics Committee of the First Affili-
ated Hospital, School of Medicine, Zhejiang University.
Informed consent was obtained from each patient included
in the study. The databases of all patients with liver cirrho-
sis admitted to The First Affiliated Hospital, College of
Medicine, Zhejiang University from 1st December 2008 to
1st May 2012 were reviewed. The follow up continued until
the date of death, the date of last hospital visit, or the end
of the study (30th July 2012). The minimum follow up
period for enrolled patients was 3 months after discharge.
Medical and microbiological records were reviewed. Pa-
tients’ demographics, duration of admission, predisposing
factors, clinical features, treatments and outcomes were
noted.
Patients with HIV negative conforming to the definition
of IPA were included. IPA was defined according to the
European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Diseases
Mycoses Study Group criteria [9]. The following factors
contributed to the diagnosis of probable IPA: positive cul-
ture of Aspergillus spp. from sputum specimens; bilateral
nodular infiltrates with central cavitation, bilateral alveolar
infiltrates or homogeneous infiltrates of the right upper
lobe; halo sign or the air-crescent sign (a macronodule sur-
rounded by a ground-glass opaque perimeter) on a com-
puted tomography (CT) scan; at least two minor clinical
findings (signs of lower respiratory tract infection, pleural
rub or the presence of any new infiltrate in a patient who
did not fulfill the major criteria but for whom no alternative
diagnosis was available). A definite diagnosis requires the
presence of fungi in tissue by biopsy or needle aspiration.
In brief, the appearance of pulmonary consolidation or in-
filtrate and rapid progression on thoracic imaging with
antibiotic-resistant fever in the appropriate host setting and
positive sputum culture was diagnosed as probable IPA.
With tissue evidence, the patient was diagnosed with
proven IPA.
The following laboratory parameters were also used to
diagnose IPA: white blood cell count, differential leuco-
cyte count, albumin, globulin, total bilirubin, inter-
national normalized ratio (INR), creatinine and
C-reactive protein (CRP), all of which were measured
using standard techniques.
SPSS version 16.0 software was used for the statistical
analyses. Continuous variables were summarized as either
mean ± SD or medians with interquartile ranges. For cat-
egorical variables, the percentages of patients were calcu-
lated. Continuous variables were compared by t-test, and
p < 0.05 was considered statistically significant for all
analyses.Results
Between December 2008 and May 2012, a total of 6,600 pa-
tients were diagnosed with liver cirrhosis and admitted to
the State Key Laboratory for Diagnosis and Treatment of
Infectious Diseases, Department of Infectious Diseases, The
First Affiliated Hospital, College of Medicine, Zhejiang Uni-
versity, China.
Out of these patients, 19 were also diagnosed with prob-
able or definite IPA according to the diagnostic criteria.
The morbility of IPA in liver cirrhosis was 0.288%. The
demographic and clinical characteristics of the 19 patients
with IPA and liver cirrhosis are presented in Table 1.
The subjects consisted of 12 men and 7 women with a
median age of 54 years (range, 30–75 years). Most of the
patients with liver cirrhosis and IPA had one or several
complications such as hepatic encephalopathy, ascites,
hemorrhage, hepatorenal syndrome or hepatic carcin-
oma. Only two patients had neutropenia. Child-
Turcotte-Pugh (CTP) scores of all patients were Child B
or C. The mean Model for End-Stage Liver Disease score
was 22 ± 7. Most patients received broad-spectrum anti-
biotics and steroids. Despite the antifungal therapy, most
(9/19) patients were dead within 7 days. Only 2 patients
survived without lung infections before the last
investigation.
All patients with IPA had mild to moderate fever
(38–39°C), cough, chest pain and crackles, while 9 patients
had hemoptysis; these were not specific symptoms but may
have been useful indicators of early stage IPA (Table 2). A
total of 16 patients presented with at least one macrono-
dule on chest CT, whose regional distribution in the lungs
was as expected (Table 2). The remaining 8 patients had at
least one halo or air-crescent sign. All patients were treated
with antifungal therapy as soon as the culture result was
positive.
Six patients were treated with caspofungin, whereas six
with voriconazole, one with itraconazole, and one with
amphotericin B. Five patients died before the culture results
were available and had not used any anti-Aspergillus agents.
Only 2 patients treated with voriconazole were still alive be-
fore the last investigation. The survival time of the 17 pa-
tients from the diagnosis of IPA was 1–162 days. Those
using itraconazole or amphotericin B all died within 7 days.
Most (4/6) of the patients taking caspofungin died within 7
days, while only one survived for 102 days. The all-causes
mortality rate of liver cirrhosis patients with IPA was
89.47% (17 of 19 patients). IPA attributable mortality was
57.89% (11/19). The rate of haemorrhage-caused mortality
was 10.53 % (2/19), while that of hepatorenal syndrome
(HRS)-attributable mortality was 21.05% (4/19).
Discussion
IPA is an opportunistic infection in immunocompromised
or immunodeficient patients. As making the early diagnosis
Table 1 Demographic and clinical characteristics of
patients with liver cirrhosis diagnosed with invasive
pulmonary aspergillosis (n = 19)
Characteristic Patients (n= 19)(%)
Sex (males/females) 12/7
Age, years, median (range) 54 (30–75)
Underlying liver disease
Hepatitis B virus 11 (57.89)
Alcoholic 3 (15.79)
Autoimmune hepatitis 1 (5.26)
Hybrid cause 4 (21.05)
Basic underlying disease
Cardiovascular disease 4 (21.05)
Diabetes mellitus type 2 2 (10.53)
Chronic lung diseases 2 (10.53)
Complications
Hepatic encephalopathy 8 (42.10)
Hepatic renal syndrome 4 (21.05)
Upper gastric bleeding 4 (21.05)
Ascites 16 (84.21)
Hydrothorax 10 (52.63)
Hepatic carcinoma 2 (10.53)
CTP scores (mean ± SD) 11 ± 2
Child B 6 (31.58)
Child C 13 (68.42)
MELD (mean ± SD) 22 ± 7
Neutropenia 2 (10.53)
Broad-spectrum antibiotics usage 18 (94.74)
One antibiotic 9 (47.37)
Two antibiotics 4 (21.05)
Three antibiotics 5 (26.32)




Data presented as n patients or mean ± SD unless stated otherwise.
CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease.
Table 2 Clinical and imaging findings and antifungal
therapy of patients with liver cirrhosis and IPA (n = 19)




Chest pain 19 (100)
Hemoptysis 9 (47.37)
Crackles 19 (100)
Imaging findings (X-ray or CT)
Changes in bilateral lung fields 16 (84.21)
Bilateral lung fields diffused 16 (84.21)
Right unilateral lung 3 (15.7)
Halo or air-crescent sign 8 (42.10)
Laboratory parameters Pre-diagnosis Post-diagnosis
CRP, mg/dL - 34.0 ± 21.1
Leukocyte counts, × 109/L 9.3 ± 5.5 11.3 ± 6.5
Neutrophil, % 74.0 ± 15.0 81.3 ± 9.3
Data presented as n patients or mean ± SD unless stated otherwise.
CT, computed tomography; CRP, C-reactive protein.
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tors have been studied to identify patients at high risk in
the hope that antifungal prophylaxis and empirical treat-
ment will improve survival. The 2004 consensus defined
cancer, whether treated or not, and hematopoietic stem cell
transplantation as host risk factors [9]. The 2009 consensus
included immunocompromised patients [10] as a new host
risk factor, but did not include critically ill patients. IPA was
mostly reported in cancer, hematopoietic stem cell trans-
plantation and liver transplantation. It has also recentlybeen described in critically ill patients, even those without
risk factors [7].
Although data have shown that invasive Aspergillus
may occur in liver transplantation [1,3,11], it has rarely
been reported in other liver diseases. Much uncertainty
remains in liver cirrhosis. In our study, about 3 per
1,000 patients with liver cirrhosis had IPA. All patients
had high CTP scores. It was suggested that severe de-
compensated liver cirrhosis may be a host risk factor for
the development of invasive aspergillosis. Other risk fac-
tors like neutropenia, diabetes and underlying pulmon-
ary diseases were present in part of the group. Most of
those patients had used antibiotics and steroids, which
could have prevented possible bacterial infections and
reduced inflammation. However, these treatments were
harmful to the host’s immune function and did not cover
all possible pathogens; therefore, patients were prone to
many types of infections caused by opportunistic patho-
gens including Aspergillus spp. Cell-mediated immunity
is the basis of fungal resistance. The respiratory epithe-
lium was usually damaged by the invasive operation and
medication in the hospital. Then insufficient secretion of
cytokines and chemokines by the macrophages also plays
an important role in the coordination of innate and
adaptive cellular responses to aspergillus infection [12].
T-lymphocyte helper (Th) cells exhibited successful se-
lection and clonal expansion of direct professional ef-
fector cells against Aspergillus [13,14]. However, as
mentioned in the literature, the lymphocyte counts were
very low and the T-lymphocyte counts were inversely re-
lated to the severity of cirrhosis [15]. Reduced cellular
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fectious morbidity of these patients with liver cirrhosis.
Both culture results and imaging findings were import-
ant for IPA diagnosis. Culture results may take longer
than imaging findings. Imaging findings, such as a halo
or air-crescent sign, are useful for the diagnosis of IPA
and could guide antifungal therapy at an early stage
[16,17]. In our study, all patients underwent CT or X-ray
imaging as well as sputum culturing. The galactomannan
(GM) test was not routinely performed to discover As-
pergillus infections earlier. As far as laboratory parame-
ters were concerned, no specific biomarkers for IPA
were available. Patients with liver cirrhosis and IPA did
not have significantly increased neutrophil numbers
(p = 0.253) or proportions (p = 0.137); however, they had
higher than normal CRP levels, which may be a clue for
the diagnosis of IPA and liver cirrhosis while combined
with imaging findings.
The mortality rates of Aspergillus infection have been
reported to be 40–90% in high-risk populations and de-
pend on host factors, infection site and treatment regi-
men applied [18]. In our study, approximately 20% of
patients were alive after the 3-month investigation, but
most died shortly after diagnosis. Multiple factors deter-
mined the survival rates. Severe cirrhosis and pulmonary
infections both induced high mortality. Invasive aspergil-
losis may increase the risk of death. Two patients were
alive in the last investigation. Organs including the lung,
brain and eyeballs were involved in proven cases. Al-
though one patient’s CTP score was C, he was young
enough to be cured by an antifungal agent and did not
have other complications.
We know that voriconazole may induce liver and kid-
ney injuries. The dose should be adjusted according to
underlying kidney and liver diseases. In the two surviv-
ing patients, we did not change the dose even with ab-
normally high total bilirubin levels, and despite the poor
prognosis of aspergillosis, liver and renal function did
not worsen after treatment and they still recovered pro-
gressively. The caspofungin dose did not need to be
changed and the patient survival time was prolonged to
up to 102 days.
Conclusions
In conclusion, patients with advanced or decompensated
liver cirrhosis were immunocompromised hosts who
were prone to IPA. Broad-spectrum antibiotics and ster-
oid usage may be predisposing factors. When a GM test
cannot be performed and symptoms of pneumonia such
as cough or hemoptysis in liver cirrhosis appear, IPA
should be considered. If a GM test can be performed as
early as possible, a patient’s prognosis may be improved.
Since gathering tissue evidence can be difficult, early
pre-emptive treatment with antifungals is warranted.Triazoles like voriconazole, itraconazole and echinocan-
din as well as caspofungin can improve patient progno-
sis. Although the use of voriconazole without adjusting
the dose did not impact negatively liver and renal func-
tion in the current study, we should closely monitor liver
and renal function effects in patients with liver cirrhosis.
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